Gilead Sciences stock (US3755581036): shares little changed as investors focus on valuation metrics

Gilead Sciences traded broadly in line with the wider US biotech sector on Nasdaq on 05/29/2026, as investors weighed the company’s income-focused profile and current valuation multiples against its product portfolio and patent cycle.

Gilead Sciences stock traded broadly in line with the wider US biotech sector on the Nasdaq on 05/29/2026, with only modest moves as investors assessed the company’s income profile and current valuation metrics against its product pipeline and HIV and oncology franchises.

The shares change hands on the Nasdaq under the ticker GILD in the United States, where many large-cap biopharma names are also listed, and the company remains a notable dividend payer in the US health care space.

As of: 29.05.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Gilead Sciences
• Sector/industry: Biopharmaceuticals, antiviral and oncology therapies
• Headquarters/country: Foster City, United States
• Core markets: North America, Europe and other international markets for HIV, liver disease, oncology and inflammatory therapies
• Key revenue drivers: HIV treatment portfolio including Biktarvy, cell therapy oncology products such as Yescarta, and other antiviral and specialty medicines
• Home exchange/listing venue: Nasdaq (GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences focuses on discovering and commercializing antiviral and oncology medicines, with sales concentrated in chronic HIV therapies and newer oncology and inflammation products that are intended to offset lifecycle pressures on mature franchises.

Valuation metrics and multiples for Gilead Sciences

Investors in the United States frequently look at Gilead Sciences through the lens of an established biopharma name that combines a sizable portfolio of marketed antiviral drugs with a consistent dividend stream, and this has positioned the stock in many US portfolios as a more income-oriented health care holding compared with some earlier-stage biotechnology peers.

The company’s valuation is commonly discussed in the context of its HIV revenue base, exposure to patent expiries over the coming years, and contributions from newer oncology and inflammation products, with US market participants comparing Gilead’s trading multiples with other large-cap drug makers listed on Nasdaq and the New York Stock Exchange.

Conclusion

Gilead Sciences shares on Nasdaq were little changed on 05/29/2026 as the market weighed the company’s established HIV franchise, dividend stream and oncology ambitions against the broader US biotech backdrop.

With valuation metrics and income characteristics in focus, many investors continue to compare Gilead’s profile with that of other large-cap biopharma names in the United States, while monitoring upcoming pipeline and regulatory milestones for signals on the company’s longer-term growth mix.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.